en
Scientific article
Open access
English

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

Published inNew England Journal of Medicine, vol. 378, no. 25, p. 2376-2385
Publication date2018
Abstract

Cisplatin chemotherapy and surgery are effective treatments for children with standard-risk hepatoblastoma but may cause considerable and irreversible hearing loss. This trial compared cisplatin with cisplatin plus delayed administration of sodium thiosulfate, aiming to reduce the incidence and severity of cisplatin-related ototoxic effects without jeopardizing overall and event-free survival.

Keywords
  • Adolescent
  • Child
  • Child
  • Preschool
  • Cisplatin/administration & dosage/adverse effects
  • Doxorubicin/administration & dosage
  • Drug Therapy
  • Combination
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Hearing Loss/chemically induced/prevention & control
  • Hepatoblastoma/drug therapy/mortality
  • Humans
  • Incidence
  • Infant
  • Liver Neoplasms/drug therapy/mortality
  • Male
  • Single-Blind Method
  • Survival Analysis
  • Thiosulfates/administration & dosage/adverse effects/therapeutic use
Citation (ISO format)
BROCK, Penelope R et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. In: New England Journal of Medicine, 2018, vol. 378, n° 25, p. 2376–2385. doi: 10.1056/NEJMoa1801109
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0028-4793
281views
356downloads

Technical informations

Creation11/06/2019 9:22:00 AM
First validation11/06/2019 9:22:00 AM
Update time03/15/2023 6:42:02 PM
Status update03/15/2023 6:42:00 PM
Last indexation01/17/2024 8:41:57 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack